While Gilead buying Immunomedics sounds cool, does it bring a trading opportunity? Pete and Frank dissect the changing biotech landscape and its effects on stock index futures. The guys look for potential trades in the stock, its options, and futures that track it.
Frank crunches many numbers to arrive at the move in IMMU's effect on Small Technology 60 futures. He then compares those numbers to alternative futures and concludes that everything seems to be on the up and up, which leaves little in the way of inspiring trade opportunities.